Inflammation and portal hypertension - The undiscovered country

Journal of Hepatology

Volumn 61, Issue 1, 2014, Pages 155-163

  Mehta, Gautam ^a   Gustot, Thierry ^b,c   Mookerjee, Rajeshwar P ^a   Garcia Pagan, Juan Carlos ^d   Fallon, Michael B ^e   Shah, Vijay H ^f   Moreau, Richard ^g,h,i   Jalan, Rajiv ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c ERASME HOSPITAL   (Belgium)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^f MAYO CLINIC   (United States)

^g CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ BEAUJON HOSPITAL   (France)

Author keywords

Cirrhosis; Inflammation; Liver failure; Portal hypertension; Variceal bleeding

Indexed keywords

ALCOHOL LIVER DISEASE; ANGIOGENESIS; BACTERIAL PERITONITIS; BACTERIAL TRANSLOCATION; BLOOD VESSEL TONE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FIBROGENESIS; HEPATIC ENCEPHALOPATHY; HUMAN; INFLAMMATION; INNATE IMMUNITY; INTESTINE FLORA; KUPFFER CELL; LIVER CELL; LIVER CIRRHOSIS; LIVER FIBROSIS; MESENTERY LYMPH NODE; PATHOGENESIS; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; REVIEW; SCAR FORMATION; SPLANCHNIC BLOOD FLOW; STELLATE CELL; VASCULAR RESISTANCE; COMPLICATION; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HYPERTENSION, PORTAL; IMMUNOLOGY; LIVER; MICROFLORA; PATHOPHYSIOLOGY; VASCULARIZATION; VASODILATATION;

ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYPERTENSION, PORTAL; IMMUNITY, INNATE; INFLAMMATION; LIVER; MICROBIOTA; SPLANCHNIC CIRCULATION; VASCULAR RESISTANCE; VASODILATION;

EID: 84902674056     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.03.014     Document Type: Review

References (85)

1. J. Bosch, J.G. Abraldes, A. Berzigotti, and J.C. Garcia-Pagan The clinical use of HVPG measurements in chronic liver disease Nat Rev Gastroenterol Hepatol 6 2009 573 582
2. Y. Iwakiri, M. Grisham, and V. Shah Vascular biology and pathobiology of the liver: report of a single-topic symposium Hepatology 47 2008 1754 1763
3. R.J. Groszmann, G. Garcia-Tsao, J. Bosch, N.D. Grace, A.K. Burroughs, and R. Planas et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis N Engl J Med 353 2005 2254 2261
4. C. Ripoll, R. Groszmann, G. Garcia-Tsao, N. Grace, A. Burroughs, and R. Planas et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis Gastroenterology 133 2007 481 488
5. M. Rosselli, J. MacNaughtan, R. Jalan, and M. Pinzani Beyond scoring: a modern interpretation of disease progression in chronic liver disease Gut 62 2013 1234 1241
6. R. Jalan, P. Gines, J.C. Olson, R.P. Mookerjee, R. Moreau, and G. Garcia-Tsao et al. Acute-on chronic liver failure J Hepatol 57 2013 1336 1348
7. R. Moreau, R. Jalan, P. Gines, M. Pavesi, P. Angeli, and J. Cordoba et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis Gastroenterology 144 2013 1426 1437 [1437 e1421-1429]
8. R.P. Mookerjee, C. Lackner, R. Stauber, V. Stadlbauer, M. Deheragoda, and A. Aigelsreiter et al. The role of liver biopsy in the diagnosis and prognosis of patients with acute deterioration of alcoholic cirrhosis J Hepatol 55 2011 1103 1111
9. D. Rincon, O. Lo Iacono, C. Ripoll, J. Gomez-Camarero, M. Salcedo, and M.V. Catalina et al. Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis Aliment Pharmacol Ther 25 2007 841 848
10. R. Wiest, and G. Garcia-Tsao Bacterial translocation (BT) in cirrhosis Hepatology 41 2005 422 433
11. I. Cirera, T.M. Bauer, M. Navasa, J. Vila, L. Grande, and P. Taura et al. Bacterial translocation of enteric organisms in patients with cirrhosis J Hepatol 34 2001 32 37
12. A. Albillos, A. de la Hera, M. Gonzalez, J.L. Moya, J.L. Calleja, and J. Monserrat et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement Hepatology 37 2003 208 217
13. H. Neugebauer, P. Hartmann, S. Krenn, T. Gluck, J. Scholmerich, and R. Straub et al. Bacterial translocation increases phagocytic activity of polymorphonuclear leucocytes in portal hypertension: priming independent of liver cirrhosis Liver Int 28 2008 1149 1157
14. T. Serste, N. Bourgeois, D. Lebrec, S. Evrard, J. Deviere, and O. Le Moine Relationship between the degree of portal hypertension and the onset of spontaneous bacterial peritonitis in patients with cirrhosis Acta Gastroenterol Belg 69 2006 355 360
15. J. Goulis, A. Armonis, D. Patch, C. Sabin, L. Greenslade, and A.K. Burroughs Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage Hepatology 27 1998 1207 1212
16. R.F. Schwabe, E. Seki, and D.A. Brenner Toll-like receptor signaling in the liver Gastroenterology 130 2006 1886 1900
17. P. Bellot, J.C. Garcia-Pagan, R. Frances, J.G. Abraldes, M. Navasa, and M. Perez-Mateo et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis Hepatology 52 2010 2044 2052
18. L. Ruiz-del-Arbol, J. Urman, J. Fernandez, M. Gonzalez, M. Navasa, and A. Monescillo et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis Hepatology 38 2003 1210 1218
19. C.J. Steib, A.C. Hartmann, C. v Hesler, A. Benesic, M. Hennenberg, and M. Bilzer et al. Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis Lab Invest 90 2010 1024 1032
20. V. Arroyo, M. Navasa, and A. Rimola Spontaneous bacterial peritonitis in liver cirrhosis: treatment and prophylaxis Infection 22 1994 S167 S175
21. Q. Zhu, L. Zou, K. Jagavelu, D.A. Simonetto, R.C. Huebert, and Z.D. Jiang et al. Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice J Hepatol 56 2012 893 899
22. B. Rasaratnam, D. Kaye, G. Jennings, F. Dudley, and J. Chin-Dusting The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial Ann Intern Med 139 2003 186 193
23. J. Vlachogiannakos, A.S. Saveriadis, N. Viazis, I. Theodoropoulos, K. Foudoulis, and S. Manolakopoulos et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis Aliment Pharmacol Ther 29 2009 992 999
24. W. Kemp, J. Colman, K. Thompson, A. Madan, M. Vincent, and J. Chin-Dusting et al. Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial Liver Int 29 2009 427 433
25. R.P. Mookerjee, S. Sen, N.A. Davies, S.J. Hodges, R. Williams, and R. Jalan Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis Gut 52 2003 1182 1187
26. A. Lemmers, T. Gustot, A. Durnez, S. Evrard, C. Moreno, and E. Quertinmont et al. An inhibitor of interleukin-6 trans-signalling, sgp130, contributes to impaired acute phase response in human chronic liver disease Clin Exp Immunol 156 2009 518 527
27. C. Mortensen, O. Andersen, A. Krag, F. Bendtsen, and S. Moller High-sensitivity C-reactive protein levels predict survival and are related to haemodynamics in alcoholic cirrhosis Eur J Gastroenterol Hepatol 24 2012 619 626
28. M.K. Mittal, T.K. Gupta, F.Y. Lee, C.C. Sieber, and R.J. Groszmann Nitric oxide modulates hepatic vascular tone in normal rat liver Am J Physiol 267 1994 G416 G422
29. D.C. Rockey, and J.J. Chung Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension Gastroenterology 114 1998 344 351
30. R.P. Mookerjee, M. Malaki, N.A. Davies, S.J. Hodges, R.N. Dalton, and C. Turner et al. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis Hepatology 45 2007 62 71
31. V. Shah, M. Toruner, F. Haddad, G. Cadelina, A. Papapetropoulos, and K. Choo et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat Gastroenterology 117 1999 1222 1228
32. 4 cirrhosis Hepatology 44 2006 44 52
33. D.C. Rockey, and R.A. Weisiger Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance Hepatology 24 1996 233 240
34. S. Fiorucci, E. Antonelli, A. Mencarelli, S. Orlandi, B. Renga, and G. Rizzo et al. The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis Hepatology 42 2005 539 548
35. R. Bataller, P. Gines, J.M. Nicolas, M.N. Gorbig, E. Garcia-Ramallo, and X. Gasull et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells Gastroenterology 118 2000 1149 1156
36. M. Graupera, S. March, P. Engel, J. Rodes, J. Bosch, and J.C. Garcia-Pagan Sinusoidal endothelial COX-1-derived prostanoids modulate the hepatic vascular tone of cirrhotic rat livers Am J Physiol Gastrointest Liver Physiol 288 2005 G763 G770
37. K. Taura, S. De Minicis, E. Seki, E. Hatano, K. Iwaisako, and C.H. Osterreicher et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis Gastroenterology 135 2008 1729 1738
38. M. Fernandez, M. Mejias, E. Garcia-Pras, R. Mendez, J.C. Garcia-Pagan, and J. Bosch Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats Hepatology 46 2007 1208 1217
39. E. Seki, S. De Minicis, C.H. Osterreicher, J. Kluwe, Y. Osawa, and D.A. Brenner et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis Nat Med 13 2007 1324 1332
40. K. Jagavelu, C. Routray, U. Shergill, S.P. O'Hara, W. Faubion, and V.H. Shah Endothelial cell toll-like receptor 4 regulates fibrosis-associated angiogenesis in the liver Hepatology 52 2010 590 601
41. P. Mandrekar, and G. Szabo Signalling pathways in alcohol-induced liver inflammation J Hepatol 50 2009 1258 1266
42. M.D. Wheeler, H. Kono, M. Yin, M. Nakagami, T. Uesugi, and G.E. Arteel et al. The role of Kupffer cell oxidant production in early ethanol-induced liver disease Free Radic Biol Med 31 2001 1544 1549
43. C.J. Steib, M. Bilzer, M. op den Winkel, S. Pfeiler, A.C. Hartmann, and M. Hennenberg et al. Treatment with the leukotriene inhibitor montelukast for 10 days attenuates portal hypertension in rat liver cirrhosis Hepatology 51 2010 2086 2096
44. O. Waidmann, F. Brunner, E. Herrmann, S. Zeuzem, A. Piiper, and B. Kronenberger Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis J Hepatol 58 2013 956 961
45. J. Gracia-Sancho, B. Lavina, A. Rodriguez-Vilarrupla, H. Garcia-Caldero, M. Fernandez, and J. Bosch et al. Increased oxidative stress in cirrhotic rat livers: a potential mechanism contributing to reduced nitric oxide bioavailability Hepatology 47 2008 1248 1256
46. 4 cirrhotic rats with portal hypertension Gut 58 2009 118 125
47. A. Karaa, W.S. Kamoun, and M.G. Clemens Oxidative stress disrupts nitric oxide synthase activation in liver endothelial cells Free Radic Biol Med 39 2005 1320 1331
48. J. Leiper, M. Nandi, B. Torondel, J. Murray-Rust, M. Malaki, and B. O'Hara et al. Disruption of methylarginine metabolism impairs vascular homeostasis Nat Med 13 2007 198 203
49. R.P. Mookerjee, A. Wiesenthal, A. Icking, S.J. Hodges, N.A. Davies, and K. Schilling et al. Increased gene and protein expression of the novel eNOS regulatory protein NOSTRIN and a variant in alcoholic hepatitis Gastroenterology 132 2007 2533 2541
50. D. Thabut, K.A. Tazi, D. Bonnefont-Rousselot, M. Aller, O. Farges, and M.C. Guimont et al. High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats Hepatology 46 2007 1893 1906
51. P. Kubes, and W.Z. Mehal Sterile inflammation in the liver Gastroenterology 143 2012 1158 1172
52. J.H. Kim, S.J. Kim, I.S. Lee, M.S. Lee, S. Uematsu, and S. Akira et al. Bacterial endotoxin induces the release of high mobility group box 1 via the IFN-beta signaling pathway J Immunol 182 2009 2458 2466
53. L.D. DeLeve, X. Wang, L. Hu, M.K. McCuskey, and R.S. McCuskey Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation Am J Physiol Gastrointest Liver Physiol 287 2004 G757 G763
54. L.D. Deleve, X. Wang, and Y. Guo Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence Hepatology 48 2008 920 930
55. J.G. Abraldes, Y. Iwakiri, M. Loureiro-Silva, O. Haq, W.C. Sessa, and R.J. Groszmann Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state Am J Physiol Gastrointest Liver Physiol 290 2006 G980 G987
56. Y. Iwakiri, G. Cadelina, W.C. Sessa, and R.J. Groszmann Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension Am J Physiol Gastrointest Liver Physiol 283 2002 G1074 G1081
57. N.G. Theodorakis, Y.N. Wang, N.J. Skill, M.A. Metz, P.A. Cahill, and E.M. Redmond et al. The role of nitric oxide synthase isoforms in extrahepatic portal hypertension: studies in gene-knockout mice Gastroenterology 124 2003 1500 1508
58. R. Moreau, E. Barriere, K.A. Tazi, B. Lardeux, D. Dargere, and W. Urbanowicz et al. Terlipressin inhibits in vivo aortic iNOS expression induced by lipopolysaccharide in rats with biliary cirrhosis Hepatology 36 2002 1070 1078
59. M. Kajita, T. Murata, K. Horiguchi, M. Iizuka, M. Hori, and H. Ozaki INOS expression in vascular resident macrophages contributes to circulatory dysfunction of splanchnic vascular smooth muscle contractions in portal hypertensive rats Am J Physiol Heart Circ Physiol 300 2011 H1021 H1031
60. T. Saetre, Y. Gundersen, C. Thiemermann, P. Lilleaasen, and A.O. Aasen Aminoethyl-isothiourea, a selective inhibitor of inducible nitric oxide synthase activity, improves liver circulation and oxygen metabolism in a porcine model of endotoxemia Shock 9 1998 109 115
61. C. Thiemermann, H. Ruetten, C.C. Wu, and J.R. Vane The multiple organ dysfunction syndrome caused by endotoxin in the rat: attenuation of liver dysfunction by inhibitors of nitric oxide synthase Br J Pharmacol 116 1995 2845 2851
62. R. Jalan, S.W. Olde Damink, J.C. Ter Steege, D.N. Redhead, A. Lee, and P.C. Hayes et al. Acute endotoxemia following transjugular intrahepatic stent-shunt insertion is associated with systemic and cerebral vasodilatation with increased whole body nitric oxide production in critically ill cirrhotic patients J Hepatol 54 2011 265 271
63. K.A. Tazi, R. Moreau, P. Herve, A. Dauvergne, D. Cazals-Hatem, and F. Bert et al. Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signaling Gastroenterology 129 2005 303 314
64. S. Batkai, Z. Jarai, J.A. Wagner, S.K. Goparaju, K. Varga, and J. Liu et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis Nat Med 7 2001 827 832
65. J. Ros, J. Claria, J. To-Figueras, A. Planaguma, P. Cejudo-Martin, and G. Fernandez-Varo et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat Gastroenterology 122 2002 85 93
66. Y.Y. Yang, H.C. Lin, Y.T. Huang, T.Y. Lee, M.C. Hou, and Y.W. Wang et al. Roles of anandamide in the hepatic microcirculation in cirrhotic rats Am J Physiol Gastrointest Liver Physiol 290 2006 G328 G334
67. K. Varga, J.A. Wagner, D.T. Bridgen, and G. Kunos Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension FASEB J 12 1998 1035 1044
68. C.B. Herath, J.S. Lubel, Z. Jia, E. Velkoska, D. Casley, and L. Brown et al. Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2 Am J Physiol Gastrointest Liver Physiol 297 2009 G98 G106
69. P.E. Rautou, J. Bresson, Y. Sainte-Marie, A.C. Vion, V. Paradis, and J.M. Renard et al. Abnormal plasma microparticles impair vasoconstrictor responses in patients with cirrhosis Gastroenterology 143 2012 e166
70. N.M. Bass, K.D. Mullen, A. Sanyal, F. Poordad, G. Neff, and C.B. Leevy et al. Rifaximin treatment in hepatic encephalopathy N Engl J Med 362 2010 1071 1081
71. S.M. Opal, P.F. Laterre, B. Francois, S.P. LaRosa, D.C. Angus, and J.P. Mira et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial JAMA 309 2013 1154 1162
72. M. Trauner, A. Baghdasaryan, T. Claudel, P. Fickert, E. Halilbasic, and T. Moustafa et al. Targeting nuclear bile acid receptors for liver disease Dig Dis 29 2011 98 102
73. T. Hu, M. Chouinard, A.L. Cox, P. Sipes, M. Marcelo, and J. Ficorilli et al. Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation J Biol Chem 281 2006 39831 39838
74. B. Vairappan, V. Sharama, A. Winstanley, N. Davies, N. Shah, and R. Jalan Modulation of the DDAH-ADMA pathway with the Farnesoid X receptor (FXR) agonist INT-747 restores hepatic eNOS activity and lowers portal pressure in cirrhotic rats Hepatology 50 2009 336A 337A
75. R. Mookerjee, M. Baenas, G. Mehta, T. Beecher Jones, and R. Hooshmand-Rad Effect of the FXR Agonist Obeticholic acid on portal pressure in alcoholic cirrhosis: a proof of concept Phase 2a study Hepatology 56 2012 LB20
76. 4 cirrhotic rats J Hepatol 46 2007 1040 1046
77. G. Marrone, L. Russo, E. Rosado, D. Hide, G. Garcia-Cardena, and J.C. Garcia-Pagan et al. The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins J Hepatol 58 2012 98 103
78. S.W. Lai, K.F. Liao, H.C. Lai, C.H. Muo, F.C. Sung, and P.C. Chen Statin use and risk of hepatocellular carcinoma Eur J Epidemiol 28 2013 485 492
79. S. Tugues, G. Fernandez-Varo, J. Munoz-Luque, J. Ros, V. Arroyo, and J. Rodes et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats Hepatology 46 2007 1919 1926
80. D. Thabut, C. Routray, G. Lomberk, U. Shergill, K. Glaser, and R. Huebert et al. Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis Hepatology 54 2011 573 585
81. M. Pinter, W. Sieghart, T. Reiberger, N. Rohr-Udilova, A. Ferlitsch, and M. Peck-Radosavljevic The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma - a pilot study Aliment Pharmacol Ther 35 2012 83 91
82. S. Bala, M. Marcos, K. Kodys, T. Csak, D. Catalano, and P. Mandrekar et al. Up-regulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor alpha (TNF alpha) production via increased mRNA half-life in alcoholic liver disease J Biol Chem 286 2011 1436 1444
83. G. Mehta, N. Shah, V. Sharma, A. Habtesion, N. Davies, and R. Jalan et al. Hepatic dimethylarginine dimethylaminohydrolase-1 (DDAH-1) is decreased in acute-on-chronic liver failure due to post-transcriptional regulation by an altered microRNA profile Hepatology 56 2012 739A
84. H.L. Janssen, H.W. Reesink, E.J. Lawitz, S. Zeuzem, M. Rodriguez-Torres, and K. Patel et al. Treatment of HCV infection by targeting microRNA N Engl J Med 368 2013 1685 1694
85. G. Mehta, R. Jalan, and R.P. Mookerjeee Cracking the ENCODE: from transcription to therapeutics Hepatology 57 2013 2532 2535